| Providing Expert Consulting for New Drug and Medical Device Development
JNPMEDI, a clinical trial consulting and data management platform company led by CEO Kwunho Jeong, has been selected as a provider in the consulting-management and technology strategy segment of the ‘2025 SME Innovation Voucher Program' organized by the Ministry of SMEs and Startups.
This program aims to enhance the competitiveness of small and medium enterprises (SMEs) by offering tailored services such as consulting, technology support, and marketing in the form of vouchers. SMEs can cover up to 90% of the total cost through government subsidies, significantly reducing financial burdens.
With this selection, JNPMEDI will support the entire process of research, development, and commercialization of pharmaceuticals and medical devices, helping SMEs innovate and expand into global markets. Notably, the company plans to leverage its AI-powered data platform, ‘Maven Clinical Cloud’, to provide integrated consulting services, including clinical trial data management and analysis, global regulatory compliance, and commercialization strategy development.
Key services offered by JNPMEDI include setting the Target Product Profile (TPP) and market forecasting in the early stages of product development, preparing for approvals from global regulatory agencies such as the FDA and CE, strategic clinical trial design, and data management. Through these services, companies can not only save time and costs but also maximize development efficiency through data-driven decision-making.
CEO Kwunho Jeong stated, “Our selection as a provider reflects the recognition of our expertise and technological capabilities across the entire pharmaceutical and medical device development lifecycle. We will do our utmost to help domestic SMEs strengthen their global competitiveness through government support.”
Through this program, JNPMEDI aims to establish itself as a reliable partner, enabling domestic medical technology companies to meet international regulatory requirements and succeed in global markets.
| Providing Expert Consulting for New Drug and Medical Device Development
JNPMEDI, a clinical trial consulting and data management platform company led by CEO Kwunho Jeong, has been selected as a provider in the consulting-management and technology strategy segment of the ‘2025 SME Innovation Voucher Program' organized by the Ministry of SMEs and Startups.
This program aims to enhance the competitiveness of small and medium enterprises (SMEs) by offering tailored services such as consulting, technology support, and marketing in the form of vouchers. SMEs can cover up to 90% of the total cost through government subsidies, significantly reducing financial burdens.
With this selection, JNPMEDI will support the entire process of research, development, and commercialization of pharmaceuticals and medical devices, helping SMEs innovate and expand into global markets. Notably, the company plans to leverage its AI-powered data platform, ‘Maven Clinical Cloud’, to provide integrated consulting services, including clinical trial data management and analysis, global regulatory compliance, and commercialization strategy development.
Key services offered by JNPMEDI include setting the Target Product Profile (TPP) and market forecasting in the early stages of product development, preparing for approvals from global regulatory agencies such as the FDA and CE, strategic clinical trial design, and data management. Through these services, companies can not only save time and costs but also maximize development efficiency through data-driven decision-making.
CEO Kwunho Jeong stated, “Our selection as a provider reflects the recognition of our expertise and technological capabilities across the entire pharmaceutical and medical device development lifecycle. We will do our utmost to help domestic SMEs strengthen their global competitiveness through government support.”
Through this program, JNPMEDI aims to establish itself as a reliable partner, enabling domestic medical technology companies to meet international regulatory requirements and succeed in global markets.